Sunnyvale, CA (PRWEB) January 15, 2014
Freeslate, Inc., the leading provider of high throughput research solutions, today announced that Lupin Limited, one of India’s top five pharmaceutical companies, has received delivery of Freeslate’s CM Protégé PharmD System for high throughput solid form screening.
Lupin, headquartered in Mumbai, India, is focused on a wide range of quality, affordable generic and branded formulations and Active Pharmaceutical Ingredients (APIs) for the developed and developing markets of the world. Lupin has selected Freeslate’s CM Protégé PharmD System to accelerate polymorph screening, automating a formerly manual process and thereby increasing their throughput. The company expects to be able to perform more experiments with less material to support the expansion of their Novel Drug Discovery and Development Program.
“We are looking forward to using Freeslate’s CM Protégé PharmD System to accelerate our Novel Drug Discovery and Development Program,” said Mr. Raj Khamboj, President NDDS at Lupin. “We believe we will achieve a ten-fold improvement in throughput using the new system resulting in significant new discoveries that provide real benefits to patients.”
“Our CM Protégé PharmD System brings exciting capabilities to solid form screening and we’re pleased that Lupin sees it as a powerful tool for accelerating their development activities,” said John S. Senaldi, President and CEO of Freeslate. “As we focus on expansion in Asia and India, the CM Protégé PharmD System opens up opportunities for many more labs to adopt Freeslate’s cutting edge technology.”
Freeslate’s CM Protégé PharmD System brings the benefits of high throughput solid and solubility screening to a broader range of researchers with an easy-to-use, fully automated platform. The System can evaluate up to 384 crystallization conditions per run to rapidly turn around solid form screening projects. Solid forms can be analyzed by birefringence, x-ray powder diffraction, and Raman spectroscopy directly from the glass Universal Substrate without any manual manipulation of fragile crystals. Other analyses and additional experiments, such as solid form stability, can also be conducted directly on the glass Universal Substrate. Heating, cooling, and mixing on-deck allows for simultaneous slurry, precipitation, cooling, and evaporation experiments on a single platform.
The CM Protégé PharmD System uses Freeslate’s Lab Execution and Analysis (LEA) software for library design, protocol development/execution, data analysis, and reporting. This allows users to design complex experiments quickly using its logical, recipe-oriented approach, and experimental conditions can be linked to analytical data for easy viewing and reporting.
Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.